Anzeige
Mehr »
Donnerstag, 26.02.2026 - Börsentäglich über 12.000 News
Während Washington Kupfer strategisch erklärt, schärft diese Aktie ihr Modell
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
254 Leser
Artikel bewerten:
(1)

Datatrak International: DATATRAK Standalone eConsent Accelerates Clinical Trials

eConsent solution deploys in under four weeks, integrates with any EDC, and delivers affordable, patient-centric digital consent

AUSTIN, TX / ACCESS Newswire / February 26, 2026 / DATATRAK International, Inc.'s (OTC:DTRK) DATATRAK Powered by Fountayn unified eClinical, eSource, and decentralized clinical trial (DCT) platform, announces the release of its standalone eConsent solution designed to help sponsors, CROs, and sites modernize informed consent while reducing startup timelines and technology costs. The new eConsent offering can be deployed in under four weeks and is available as a lightweight, cost-effective module or as a fully integrated component of the DATATRAK Powered by Fountayn EDC and DCT ecosystem.

Unlike many eConsent tools that are bundled only within large, expensive ePRO or DCT packages, DATATRAK's standalone eConsent delivers flexible pricing so study teams can implement digital informed consent without paying for an entire ePRO system they do not need. Reasonable, study-level pricing makes eConsent accessible for a broader range of trials and budgets, including early-phase, single-site, and investigator-initiated studies.

"Study teams want the benefits of modern eConsent-faster startup, better participant understanding, and cleaner documentation-without lengthy implementations or bloated platform costs," said Alex Tabatabai, CEO, DATATRAK. "Our standalone eConsent is purpose-built to launch quickly, fit into existing study infrastructure, and scale seamlessly when sponsors are ready to expand into DATATRAK EDC, ePRO, RTSM, CTMS, or full decentralized clinical trials."

Fast Startup, IND-Ready Timelines

The DATATRAK eConsent solution is designed for implementation timelines of under four weeks, allowing study teams to go live in time for IND or ethics approval and first-patient-in milestones. Configuration is supported by reusable templates and best-practice workflows that help streamline approvals and site activation.

Standalone eConsent with Enterprise-Grade Integration

The eConsent module can be used as a standalone utility and integrated with third-party infrastructure, including external EDC, RTSM, CTMS, and eTMF systems, or deployed as a native component of DATATRAK EDC. When used with DATATRAK EDC, consent data and enrollment status are seamlessly connected to subject records, randomization, and visit schedules, enabling true end-to-end digital trial execution on a single platform.

Key Capabilities Include:

1. Standalone eConsent that integrates with third-party clinical trial systems or EDC
2. Seamless integration with the consent and enrollment workflow in EDC
3. Support for remote and decentralized clinical trials with patient access from any device
4. Designed for protocol amendments and regulatory workflows

DATATRAK's eConsent simplifies managing protocol amendments and re-consent, a common pain point for sponsors and sites. Study teams can easily trigger and track re-consent when protocol changes occur, ensuring every participant is on the correct version and that audit trails remain inspection-ready.

The system also supports tracking and managing supporting documents such as witness statements, translations, and supplemental information, helping maintain complete, compliant records across sites and regions.

Flexible Patient Engagement and Enrollment Options

To support both site-based and remote enrollment, the eConsent solution enables sites to invite participants using multiple methods: email links, QR codes patients can scan on their own device, or direct registration by the physician or site staff. Sites can also schedule consent visits prior to trial enrollment, helping ensure participants have adequate time to review materials, ask questions, and complete consent in a controlled, compliant workflow.

When combined with DATATRAK's EDC, ePRO, and eSource capabilities, sponsors can extend the same patient-centric digital experience beyond consent to ongoing data collection and engagement throughout the study.

About DATATRAK

DATATRAK Powered by Fountayn is transforming healthcare and life sciences through technological innovations by providing a unified, cloud based eClinical and decentralized clinical trial platform that brings together EDC, eSource, ePRO/eCOA, eConsent, RTSM, RBM, Adjudication, Imaging, Safety, Global Oversight and Enterprise Workflow Management, CTMS, eTMF, and DCT tools in a single, configurable environment. With global access from any device and a single-source data model, DATATRAK helps sponsors, CROs, and sites accelerate study timelines, improve data quality, and reduce operational burden across all phases of clinical research. DATATRAK complies with the highest Quality Assurance standards that are 21 CFR Part 11, GDPR, GCP, HIPAA, and CDISC compliant that are fully validated by our experienced team of software quality engineers. DATATRAK's cloud-based platform is trusted in 83 countries, 6 continents, for over 10,000 clinical trials. DATATRAK is based in Austin, Texas and has team members and data hosting infrastructure in its key service regions of the United States, Europe, and Japan. For more information, visit www.fountayn.com or www.datatrak.com.

Contact: sales@fountayn.com

SOURCE: Datatrak International



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/datatrak-standalone-econsent-accelerates-clinical-trials-1141923

© 2026 ACCESS Newswire
Tech-Aktien schwanken – 3 Versorger mit Rückenwind
Die Stimmung an den Märkten hat sich grundlegend gedreht. Während Tech- und KI-Werte zunehmend mit Volatilität und Bewertungsrisiken kämpfen, erleben klassische Versorger ein unerwartetes Comeback. Laut IEA und EIA steigt der globale Strombedarf strukturell weiter, nicht nur wegen E-Mobilität und Wärmepumpen, sondern vor allem durch energiehungrige KI-Rechenzentren. Energie wird damit zur zentralen Infrastruktur des digitalen Zeitalters.

Gleichzeitig rücken in unsicheren Marktphasen stabile Cashflows, solide Bilanzen und regulierte Renditen wieder stärker in den Fokus. Genau hier spielen Versorger ihre Stärken aus: berechenbare Erträge, robuste Nachfrage und hohe Dividenden – Qualitäten, die vielen Wachstumswerten aktuell fehlen.

Nach Jahren im Schatten der Tech-Rallye steigt nun das Interesse an Unternehmen, die Stabilität mit langfristigen Wachstumsthemen wie Netzausbau, Dekarbonisierung und erneuerbaren Energien verbinden.

Im aktuellen Spezialreport stellen wir drei Versorger vor, die defensive Stärke mit attraktivem Potenzial kombinieren.

Jetzt den kostenlosen Report sichern – bevor die nächste Versorgerwelle Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.